• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外泌体递送的 PD-L1 siRNA 和 CTLA-4 siRNA 可防止结直肠癌的生长和肿瘤免疫逃逸。

Exosomes-delivered PD-L1 siRNA and CTLA-4 siRNA protect against growth and tumor immune escape in colorectal cancer.

机构信息

Department of Colorectal and Anal Surgery, General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China.

Xiangya Pharmaceutical College, Central South University, Changsha, Hunan 410013, PR China.

出版信息

Genomics. 2023 Jul;115(4):110646. doi: 10.1016/j.ygeno.2023.110646. Epub 2023 May 20.

DOI:10.1016/j.ygeno.2023.110646
PMID:37217085
Abstract

OBJECTIVE

This study aims to dissect impacts of exosomes-delivered PD-L1 and CTLA-4 siRNAs on colorectal cancer (CRC) progression and immune responses.

METHODS

Exosomes containing PD-L1 siRNA and CTLA-4 siRNA were prepared and utilized to treat CRC cells to evaluate their effects. A tumor-bearing mouse model was established for verification.

RESULTS

Exosomes containing PD-L1 siRNA and CTLA-4 siRNA repressed malignant features of CRC cells and restrained tumor growth and activated tumor immune responses in vivo. Co-culture of CRC cells treated with exosomes containing PD-L1 siRNA and CTLA-4 siRNA with human CD8 T cells increased the percentage of CD8 T cells, decreased the apoptotic rate of CD8 T cells, elevated IL-2, IFN-γ, and TNF-α expression in cell supernatants, reduced adherent density of CRC cells, augmented the positive rate of CRC cells, and subdued tumor immune escape.

CONCLUSION

Exosomes containing PD-L1 siRNA and CTLA-4 siRNA suppressed CRC progression and enhanced tumor immune responses.

摘要

目的

本研究旨在剖析外泌体递送的 PD-L1 和 CTLA-4 siRNA 对结直肠癌(CRC)进展和免疫应答的影响。

方法

制备含有 PD-L1 siRNA 和 CTLA-4 siRNA 的外泌体,并用于处理 CRC 细胞以评估其作用。建立荷瘤小鼠模型进行验证。

结果

含有 PD-L1 siRNA 和 CTLA-4 siRNA 的外泌体抑制 CRC 细胞的恶性特征,抑制体内肿瘤生长并激活肿瘤免疫应答。用含有 PD-L1 siRNA 和 CTLA-4 siRNA 的外泌体处理的 CRC 细胞与人 CD8 T 细胞共培养,增加了 CD8 T 细胞的百分比,降低了 CD8 T 细胞的凋亡率,提高了细胞上清液中 IL-2、IFN-γ 和 TNF-α 的表达,降低了 CRC 细胞的黏附密度,增加了 CRC 细胞的阳性率,并抑制了肿瘤免疫逃逸。

结论

含有 PD-L1 siRNA 和 CTLA-4 siRNA 的外泌体抑制 CRC 进展并增强肿瘤免疫应答。

相似文献

1
Exosomes-delivered PD-L1 siRNA and CTLA-4 siRNA protect against growth and tumor immune escape in colorectal cancer.外泌体递送的 PD-L1 siRNA 和 CTLA-4 siRNA 可防止结直肠癌的生长和肿瘤免疫逃逸。
Genomics. 2023 Jul;115(4):110646. doi: 10.1016/j.ygeno.2023.110646. Epub 2023 May 20.
2
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.外泌体 PD-L1 通过免疫逃避促进非小细胞肺癌肿瘤生长。
Exp Mol Med. 2019 Aug 9;51(8):1-13. doi: 10.1038/s12276-019-0295-2.
3
The suppressive effect of co-inhibiting and expression on H22 hepatomas in mice.共抑制 和 的表达对小鼠 H22 肝癌的抑制作用。
Cell Mol Biol Lett. 2018 Dec 15;23:58. doi: 10.1186/s11658-018-0122-0. eCollection 2018.
4
Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.转化生长因子β调控肿瘤来源外泌体中 PD-L1 的富集,并调节乳腺癌中 TCR 信号转导早期磷酸化,从而介导 CD8 T 细胞功能障碍。
Carcinogenesis. 2021 Feb 11;42(1):38-47. doi: 10.1093/carcin/bgaa092.
5
Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.整合素 α2 通过增强外泌体中 PD-L1 的表达来抑制 CD8+T 细胞活性,从而促进非小细胞肺癌的免疫逃逸。
J Investig Med. 2024 Jan;72(1):57-66. doi: 10.1177/10815589231207801. Epub 2023 Dec 12.
6
Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.鼻咽癌细胞来源的外泌体 PD-L1 抑制 CD8+T 细胞活性并促进免疫逃逸。
Cancer Sci. 2022 Sep;113(9):3044-3054. doi: 10.1111/cas.15433. Epub 2022 Jul 12.
7
Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4/CD8 tumor infiltrating lymphocytes (TILs) ratio.免疫检查点蛋白(PD-L1 和 CTLA-4)在子宫内膜癌中的作用:预后作用及其与 CD4/CD8 肿瘤浸润淋巴细胞(TILs)比值的相关性。
J Immunoassay Immunochem. 2022 Mar 4;43(2):192-212. doi: 10.1080/15321819.2021.1981377. Epub 2021 Oct 26.
8
High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B.循环外泌体 PD-L1 的高表达有助于肝癌的免疫逃逸和慢性乙型肝炎的免疫清除。
Aging (Albany NY). 2024 Jul 17;16(14):11373-11384. doi: 10.18632/aging.206020.
9
LncRNA suppresses CD8 T cells to confer resistance to cetuximab in colorectal cancer via miR-20b-5p/PD-L1 axis.长链非编码 RNA 通过 miR-20b-5p/PD-L1 轴抑制 CD8 T 细胞从而赋予结直肠癌对西妥昔单抗的耐药性。
Epigenomics. 2021 Aug;13(16):1281-1297. doi: 10.2217/epi-2021-0130. Epub 2021 Sep 15.
10
Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.溶细胞活性与结直肠癌中的突变负担和免疫检查点失调表达相关。
J Exp Clin Cancer Res. 2019 Aug 20;38(1):364. doi: 10.1186/s13046-019-1372-z.

引用本文的文献

1
Extracellular Vesicles and PD-L1-A Review of Complex Immunoregulatory Properties and Clinical Importance.细胞外囊泡与程序性死亡受体1配体——复杂免疫调节特性及临床重要性综述
Biomedicines. 2025 May 31;13(6):1356. doi: 10.3390/biomedicines13061356.
2
Nanocarriers for cutting-edge cancer immunotherapies.用于前沿癌症免疫疗法的纳米载体。
J Transl Med. 2025 Apr 16;23(1):447. doi: 10.1186/s12967-025-06435-0.
3
Prospect of extracellular vesicles in tumor immunotherapy.细胞外囊泡在肿瘤免疫治疗中的前景。
Front Immunol. 2025 Feb 26;16:1525052. doi: 10.3389/fimmu.2025.1525052. eCollection 2025.
4
Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion.肿瘤细胞衍生的细胞外囊泡对免疫逃逸的影响。
Adv Sci (Weinh). 2025 Mar;12(12):e2417357. doi: 10.1002/advs.202417357. Epub 2025 Feb 3.
5
Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics.影响免疫:细胞外囊泡在肿瘤免疫检查点动态变化中的作用
Exp Mol Med. 2024 Nov;56(11):2365-2381. doi: 10.1038/s12276-024-01340-w. Epub 2024 Nov 11.
6
Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.核酸治疗药物在抗癌治疗中的最新进展与展望
Molecules. 2024 Oct 7;29(19):4737. doi: 10.3390/molecules29194737.
7
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.外泌体介导的siRNA分子在癌症治疗中的应用:成就与挑战
Front Mol Biosci. 2024 Sep 17;11:1447953. doi: 10.3389/fmolb.2024.1447953. eCollection 2024.
8
CTLA-4 silencing could promote anti-tumor effects in hepatocellular.CTLA-4 沉默可能促进肝癌的抗肿瘤作用。
Med Oncol. 2024 Jul 2;41(8):193. doi: 10.1007/s12032-024-02361-1.
9
Shedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update.解析外泌体 PD-L1(ExoPD-L1)在癌症进展中的作用:最新研究进展。
Cell Biochem Biophys. 2024 Sep;82(3):1709-1720. doi: 10.1007/s12013-024-01340-7. Epub 2024 Jun 22.
10
Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer.利用脂质纳米颗粒的miR159模拟物与伊立替康联合用于增强结直肠癌治疗
Pharmaceutics. 2024 Apr 22;16(4):570. doi: 10.3390/pharmaceutics16040570.